FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070371350> ?p ?o ?g. }

• W2070371350 endingPage "935" @default.
• W2070371350 startingPage "925" @default.
• W2070371350 abstract "To use near-infrared (NIR) optical imaging to assess the therapeutic susceptibility and drug dosing of orthotopic human breast cancers implanted in mice treated with molecularly targeted therapy.This study was approved by the institutional animal care and use committee. Imaging probes were synthesized by conjugating the human epidermal growth factor receptor type 2 (HER2)-specific antibody trastuzumab with fluorescent dyes. In vitro probe binding was assessed with flow cytometry. HER2-normal and HER2-overexpressing human breast cancer cells were orthotopically implanted in nude mice. Intravital laser scanning fluorescence microscopy was used to evaluate the in vivo association of the probe with the tumor cells. Mice bearing 3-5-mm-diameter tumors were intravenously injected with 0.4 nmol of HER2 probe before or after treatment. A total of 123 mice were used for all in vivo tumor growth and imaging experiments. Tumor fluorescence intensity was assessed, and standard fluorescence values were determined. Statistical significance was determined by performing standard analysis of variance across the imaging cohorts.HER2 probe enabled differentiation between HER2-normal and HER2-overexpressing human breast cancer cells in vitro and in vivo, with binding levels correlating with tumor trastuzumab susceptibility. Serial imaging before and during trastuzumab therapy revealed a significant reduction (P < .05) in probe binding with treatment and thus provided early evidence of successful HER2 inhibition days before the overall reduction in tumor growth was apparent.NIR imaging with HER2-specific imaging probes enables evaluation of the therapeutic susceptibility of human mammary tumors and of drug dosing during HER2-targeted therapy with trastuzumab. This approach, combined with tomographic imaging techniques, has potential in the clinical setting for determining patient eligibility for and adequate drug dosing in molecularly targeted cancer therapies." @default.
• W2070371350 created "2016-06-24" @default.
• W2070371350 creator A5003318467 @default.
• W2070371350 creator A5009308484 @default.
• W2070371350 creator A5038474417 @default.
• W2070371350 creator A5044476572 @default.
• W2070371350 creator A5063494562 @default.
• W2070371350 creator A5067255019 @default.
• W2070371350 creator A5073383259 @default.
• W2070371350 creator A5084358279 @default.
• W2070371350 creator A5088233000 @default.
• W2070371350 date "2008-09-01" @default.
• W2070371350 modified "2023-10-05" @default.
• W2070371350 title "Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/<i>neu-</i>targeted Therapy" @default.
• W2070371350 cites W1498293114 @default.
• W2070371350 cites W1534849470 @default.
• W2070371350 cites W1562776506 @default.
• W2070371350 cites W187705992 @default.
• W2070371350 cites W1975348357 @default.
• W2070371350 cites W2006016180 @default.
• W2070371350 cites W2031473351 @default.
• W2070371350 cites W2032981854 @default.
• W2070371350 cites W2033949617 @default.
• W2070371350 cites W2045190098 @default.
• W2070371350 cites W2046120865 @default.
• W2070371350 cites W2053356496 @default.
• W2070371350 cites W2053961812 @default.
• W2070371350 cites W2057458801 @default.
• W2070371350 cites W2059246878 @default.
• W2070371350 cites W2068548659 @default.
• W2070371350 cites W2078881615 @default.
• W2070371350 cites W2082117763 @default.
• W2070371350 cites W2082717401 @default.
• W2070371350 cites W2090967583 @default.
• W2070371350 cites W2101030360 @default.
• W2070371350 cites W2117061676 @default.
• W2070371350 cites W2129218935 @default.
• W2070371350 cites W2141393790 @default.
• W2070371350 cites W2146595692 @default.
• W2070371350 cites W2148199952 @default.
• W2070371350 cites W2159581345 @default.
• W2070371350 cites W2162375550 @default.
• W2070371350 doi "https://doi.org/10.1148/radiol.2482071496" @default.
• W2070371350 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2798096" @default.
• W2070371350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18647846" @default.
• W2070371350 hasPublicationYear "2008" @default.
• W2070371350 type Work @default.
• W2070371350 sameAs 2070371350 @default.
• W2070371350 citedByCount "60" @default.
• W2070371350 countsByYear W20703713502012 @default.
• W2070371350 countsByYear W20703713502013 @default.
• W2070371350 countsByYear W20703713502014 @default.
• W2070371350 countsByYear W20703713502015 @default.
• W2070371350 countsByYear W20703713502016 @default.
• W2070371350 countsByYear W20703713502017 @default.
• W2070371350 countsByYear W20703713502018 @default.
• W2070371350 countsByYear W20703713502019 @default.
• W2070371350 countsByYear W20703713502020 @default.
• W2070371350 countsByYear W20703713502021 @default.
• W2070371350 countsByYear W20703713502022 @default.
• W2070371350 crossrefType "journal-article" @default.
• W2070371350 hasAuthorship W2070371350A5003318467 @default.
• W2070371350 hasAuthorship W2070371350A5009308484 @default.
• W2070371350 hasAuthorship W2070371350A5038474417 @default.
• W2070371350 hasAuthorship W2070371350A5044476572 @default.
• W2070371350 hasAuthorship W2070371350A5063494562 @default.
• W2070371350 hasAuthorship W2070371350A5067255019 @default.
• W2070371350 hasAuthorship W2070371350A5073383259 @default.
• W2070371350 hasAuthorship W2070371350A5084358279 @default.
• W2070371350 hasAuthorship W2070371350A5088233000 @default.
• W2070371350 hasBestOaLocation W20703713502 @default.
• W2070371350 hasConcept C112705442 @default.
• W2070371350 hasConcept C121332964 @default.
• W2070371350 hasConcept C121608353 @default.
• W2070371350 hasConcept C126322002 @default.
• W2070371350 hasConcept C136339569 @default.
• W2070371350 hasConcept C142724271 @default.
• W2070371350 hasConcept C150903083 @default.
• W2070371350 hasConcept C202751555 @default.
• W2070371350 hasConcept C203014093 @default.
• W2070371350 hasConcept C207001950 @default.
• W2070371350 hasConcept C2776872082 @default.
• W2070371350 hasConcept C2779786085 @default.
• W2070371350 hasConcept C2781230642 @default.
• W2070371350 hasConcept C29331040 @default.
• W2070371350 hasConcept C502942594 @default.
• W2070371350 hasConcept C530470458 @default.
• W2070371350 hasConcept C553184892 @default.
• W2070371350 hasConcept C55493867 @default.
• W2070371350 hasConcept C57477423 @default.
• W2070371350 hasConcept C62520636 @default.
• W2070371350 hasConcept C71924100 @default.
• W2070371350 hasConcept C86803240 @default.
• W2070371350 hasConcept C91881484 @default.
• W2070371350 hasConcept C98274493 @default.
• W2070371350 hasConceptScore W2070371350C112705442 @default.
• W2070371350 hasConceptScore W2070371350C121332964 @default.
• W2070371350 hasConceptScore W2070371350C121608353 @default.

• next